Recap: Aerovate Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Aerovate Therapeutics (NASDAQ:AVTE) reported Q3 earnings with an EPS of $-0.71, missing estimates by 2.9% and showing no revenue change from the same period last year. The company's past earnings miss was followed by a 1.14% share price drop the next day.
November 13, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aerovate Therapeutics reported a Q3 EPS of $-0.71, missing estimates by 2.9%, with no revenue change from the previous year.
The earnings miss by Aerovate Therapeutics is likely to negatively impact investor sentiment in the short term, as historical data shows a previous miss led to a stock price drop. The lack of revenue growth could also contribute to a bearish outlook.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100